Valuation: CSL Limited

Market Cap 4.12TCr 3.61TCr 3.33TCr 3.07TCr 5.78TCr 3,97100Cr 5.91TCr 40TCr 16TCr 1,94400Cr 15TCr 15TCr 6,69500Cr P/E 2026 *
-46.2x
P/E 2027 * 28.7x
Enterprise Value 5.01TCr 4.38TCr 4.04TCr 3.72TCr 7.02TCr 4,82200Cr 7.18TCr 48TCr 19TCr 2,36100Cr 19TCr 18TCr 8,13200Cr EV / Sales 2026 *
3.26x
EV / Sales 2027 * 3.16x
Free-Float
99.3%
Yield 2026 *
3.31%
Yield 2027 * 3.4%
1 day+1.12%
1 week+0.35%
Current month+7.48%
1 month+15.48%
3 months-10.07%
6 months-29.74%
Current year-28.57%
1 week 120.1
Extreme 120.1
124.83
1 month 108.5
Extreme 108.5
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap.
01/06/26 Buy

Director

1,036 0.0002%
26/05/26 Buy

Chief Executive Officer

1,100 0.0002%
26/05/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%+0.35%-50.35%-52.35% 4.12TCr
-0.33%+1.83%+23.03%-6.22% 6.88TCr
+0.67%+0.93%+37.53%+198.53% 5.21TCr
+0.94%+39.60%+39.60%+39.60% 4.35TCr
-1.40%+3.43%+60.07%-26.01% 3.04TCr
-2.11%-9.45%+91.99%-49.58% 2.45TCr
+0.51%+0.46%+70.08%+91.96% 2.34TCr
-5.57%-0.84%-0.17%+174.11% 1.98TCr
-0.86%-1.99%+68.42%+124.39% 1.66TCr
+1.34%-5.25%+74.11%+154.00% 1.6TCr
Average -0.57%-1.25%+41.43%+64.84% 3.36TCr
Weighted average by Cap. -0.26%-0.31%+33.37%+52.29%

Financials

2026 *2027 *
Net sales 1.54TCr 1.35TCr 1.24TCr 1.14TCr 2.16TCr 1,48100Cr 2.2TCr 15TCr 5.83TCr 73TCr 5.78TCr 5.65TCr 2,49800Cr 1.56TCr 1.37TCr 1.26TCr 1.16TCr 2.19TCr 1,50400Cr 2.24TCr 15TCr 5.92TCr 74TCr 5.87TCr 5.74TCr 2,53600Cr
Net income -90Cr -78Cr -72Cr -67Cr -125.79Cr -8.64TCr -128.54Cr -865.34Cr -339.89Cr -4.23TCr -336.93Cr -329.5Cr -15TCr 118.48Cr 103.6Cr 96Cr 88Cr 166.11Cr 11TCr 169.75Cr 1.14TCr 448.86Cr 5.58TCr 444.95Cr 435.14Cr 19TCr
Net Debt 884.72Cr 773.56Cr 713.91Cr 657.64Cr 1.24TCr 85TCr 1.27TCr 8.53TCr 3.35TCr 42TCr 3.32TCr 3.25TCr 1,43600Cr 806.33Cr 705.02Cr 650.66Cr 599.37Cr 1.13TCr 78TCr 1.16TCr 7.78TCr 3.05TCr 38TCr 3.03TCr 2.96TCr 1,30900Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
17/26/17 A$123.32 +1.12% 16,21,401
16/26/16 A$121.95 +0.16% 10,47,549
15/26/15 A$121.75 -0.98% 9,07,829
14/26/14 A$122.96 +1.34% 6,97,252
13/26/13 A$121.34 -1.26% 15,04,392
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
86.11USD
Average target price
96.64USD
Spread / Average Target
+12.23%

Quarterly revenue - Rate of surprise